Close

Audentes Therapeutics (BOLD) Receives FDA Clearance of IND Application for AT342 to Treat Crigler-Najjar Syndrome

February 1, 2017 8:05 AM EST Send to a Friend
Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing gene therapy products for patients living ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login